Business
ARS Pharmaceuticals’ neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms
The availability of neffy 1 mg extends protection to younger, school-aged children—who make up nearly 23% of people needing epinephrine Visit neffy.com for
About this update from Ars Pharmaceuticals, Inc.
[{"type":"text","content":"The availability of neffy 1 mg extends protection to younger, school-aged children—who make up nearly 23% of people needing epinephrine Visit neffy.com for savings and support programs and pay as little as $25 (if eligible) in preparation for summer travel and back-to-school SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, announced neffy® (epinephrine nasal spray) 1 mg is now available to patients and caregivers by prescription across the U.S. In March 2025, the U.S. Food and Drug Administration approved neffy for the treatment of Type I allergic reactions, including anaphylaxis, in children who are aged four years and older and weigh 15 to “Many children fear needles, which can lead parents to delay administering needle-based epinephrine treatments. This delay may result in serious consequences,” Eric Karas, Chief Commercial Officer of ARS Pharma, states. “The availability of the 1 mg dose before summer travel, camps, and back-to-school season will help communities better prepare for allergic emergencies. The needle-free design of neffy also eliminates the risk of adverse events, such as accidental injections into the hands or fingers of a child or caregiver, which happens about 3,500 times each year. Now is a great time for parents to reach out to their healthcare providers to ask for neffy as a treatment for their young children.” neffy is small and designed to be easy-to-use, making it convenient to carry in a backpack or lunchbox. Human factor studies show one hundred percent of users dosed neffy successfully by following instructions, compared with up to 35% error rates with injection devices. The device has a shelf life of 24 months and tolerance to temperature exposures up to 122°F (50°C) based on testing for up to three months. If accidentally frozen, neffy can be thawed without impact on the product quality and reliability. ARS Pharma is committed to access and affordability, and provides comprehensive support programs to patients, caregivers, and healthcare professionals with information to guide their treatment journey, details about medication fulfillment services, financial assistance, and navigating insuran...